Loading...
•
Sep 30
ACADIA Q3 2025 Earnings Report
Acadia Pharmaceuticals reported its financial results for the third quarter ended September 30, 2025, highlighting strong revenue growth and increased sales for NUPLAZID and DAYBUE.
Key Takeaways
Acadia Pharmaceuticals delivered a strong third quarter in 2025, with total revenues reaching $278.6 million, an 11% increase year-over-year. Both NUPLAZID and DAYBUE achieved significant sales growth, driven by increased prescriptions and expanded patient reach. The company also reported a net income of $71.8 million, or $0.42 per diluted share, benefiting from a tax benefit related to the One Big Beautiful Bill Act.
Total revenues for Q3 2025 were $278.6 million, an 11% increase compared to the same period in 2024.
NUPLAZID net product sales reached a record $177.5 million, up 12% year-over-year, driven by accelerated new prescriptions.
DAYBUE net product sales were $101.1 million, an 11% increase year-over-year, attributed to field force expansion and international named patient supply programs.
Net income for the quarter was $71.8 million, or $0.42 per diluted share, significantly higher than the previous year, partly due to a tax benefit.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.comDAYBUE Sales Revenue
CapyFin.com Forward Guidance
Acadia Pharmaceuticals updated its full-year 2025 financial guidance, narrowing and raising the high end for NUPLAZID sales, and updating guidance for DAYBUE sales and total revenues. The company also provided updated ranges for R&D and SG&A expenses.
Positive Outlook
- Narrowing and raising the high end of NUPLAZID net product sales guidance to $685 million to $695 million.
- Updating total revenues guidance to a range of $1.070 billion to $1.095 billion, with the high end maintained.
- Updating DAYBUE net product sales guidance to $385 million to $400 million, reflecting continued growth.
- Updated guidance includes revenues from U.S. net product sales and named patient supply programs outside the U.S., indicating broader market reach.
- R&D expense guidance of $335 million to $345 million, showing continued investment in pipeline development.
Challenges Ahead
- No explicit negative forward guidance points were provided in the report; all updates were presented as adjustments to previous guidance ranges.